Department of Pulmonary and Critical Care Medicine, Tangdu Hospital, Air Force Medical University, Xi'an, PR China.
Department of Pulmonary and Critical Care Medicine, Tangdu Hospital, Air Force Medical University, Xi'an, PR China.
Ann Diagn Pathol. 2024 Apr;69:152261. doi: 10.1016/j.anndiagpath.2023.152261. Epub 2023 Dec 26.
Pathology is considered the gold standard for the diagnosis of lung lesions, but the pathological result is relatively lagging and cannot provide real-time guidance for the biopsy procedure.
To investigate the potential application of rapid on-site evaluation (ROSE) during flexible bronchoscopy (FB) in the evaluation and diagnosis of lung lesions.
Consecutive patients who underwent FB for the diagnosis of lung lesions between August 2022 and February 2023 were included in this retrospective study. 294 patients underwent FB with ROSE, while 304 patients underwent FB without ROSE. The final pathological results and the number of patients undergoing repeat biopsies were recorded in both groups. Specifically, we conducted separate statistical analysis for patients undergoing different biopsy methods, including the endobronchial biopsy (EBB), radial probe endobronchial ultrasound transbronchial lung biopsy with guide sheath (r-EBUS-GS-TBLB), and the endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) to study the detailed roles that ROSE plays under different biopsy methods.
The adequacy rate of biopsy specimens from the non-ROSE group was significantly lower than that of the ROSE group (259/281 = 92.17 % vs. 263/268 = 98.13 %, p = 0.001). Meanwhile, fewer patients underwent repeat biopsies in the ROSE group compared to the non-ROSE group (2/294 = 0.68 % vs. 10/304 = 3.29 %, p = 0.023). For the ROSE group, the consistency between ROSE diagnoses and final pathological diagnoses was 94.40 % (κ = 0.886), with 95.58 % for benign diseases and 93.55 % for malignant diseases.
The utility of ROSE during FB increases the adequacy rate of biopsy specimens and thus decreases the need for repeat biopsies in patients with lung lesions to get a definite diagnosis. Moreover, the high consistency between ROSE diagnoses and final pathological diagnoses suggests that ROSE is a reliable tool for optimizing the diagnosis of lung lesions.
病理学被认为是诊断肺部病变的金标准,但病理结果相对滞后,无法为活检过程提供实时指导。
探讨在纤维支气管镜(FB)检查中应用快速现场评估(ROSE)对肺部病变的评估和诊断的潜在应用。
本回顾性研究纳入了 2022 年 8 月至 2023 年 2 月期间因肺部病变而行 FB 检查的连续患者。294 例患者行 FB 检查并采用 ROSE,304 例患者行 FB 检查但不采用 ROSE。两组均记录最终病理结果和需要重复活检的患者数量。具体而言,我们针对不同的活检方法(包括经支气管镜活检术(EBB)、带鞘支气管内径向探头超声引导下经支气管肺活检术(r-EBUS-GS-TBLB)和支气管内超声引导下经支气管针吸活检术(EBUS-TBNA))分别进行了单独的统计分析,以研究 ROSE 在不同活检方法下的详细作用。
非 ROSE 组的活检标本充足率明显低于 ROSE 组(259/281=92.17%比 263/268=98.13%,p=0.001)。同时,ROSE 组需要重复活检的患者明显少于非 ROSE 组(2/294=0.68%比 10/304=3.29%,p=0.023)。对于 ROSE 组,ROSE 诊断与最终病理诊断的一致性为 94.40%(κ=0.886),良性疾病的一致性为 95.58%,恶性疾病的一致性为 93.55%。
FB 检查中应用 ROSE 可提高活检标本的充足率,从而减少肺部病变患者获得明确诊断所需的重复活检次数。此外,ROSE 诊断与最终病理诊断之间具有很高的一致性,表明 ROSE 是优化肺部病变诊断的可靠工具。